Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives Average Recommendation of “Hold” from Brokerages

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) have been given an average rating of “Hold” by the seven brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $3.75.

Several analysts have commented on the company. Weiss Ratings downgraded Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 16th. Wall Street Zen downgraded Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th.

Werewolf Therapeutics Price Performance

Shares of NASDAQ HOWL opened at $0.35 on Monday. The stock has a market cap of $17.07 million, a PE ratio of -0.28 and a beta of 0.29. Werewolf Therapeutics has a 52-week low of $0.34 and a 52-week high of $2.38. The business has a 50-day moving average price of $0.59 and a 200 day moving average price of $0.69.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. Sell-side analysts anticipate that Werewolf Therapeutics will post -1.08 earnings per share for the current year.

Insider Activity at Werewolf Therapeutics

In other Werewolf Therapeutics news, major shareholder Ra Capital Management, L.P. sold 149,625 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $0.37, for a total transaction of $55,361.25. Following the completion of the sale, the insider directly owned 331,414 shares of the company’s stock, valued at $122,623.18. This represents a 31.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Luke Evnin sold 76,928 shares of the company’s stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $0.37, for a total value of $28,463.36. Following the sale, the director directly owned 300,283 shares of the company’s stock, valued at approximately $111,104.71. This represents a 20.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 3,507,127 shares of company stock valued at $1,879,521. 23.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of large investors have recently modified their holdings of HOWL. AQR Capital Management LLC purchased a new position in shares of Werewolf Therapeutics during the 1st quarter worth approximately $79,000. Marshall Wace LLP purchased a new position in shares of Werewolf Therapeutics during the 2nd quarter worth approximately $113,000. Qube Research & Technologies Ltd purchased a new position in shares of Werewolf Therapeutics during the 2nd quarter worth approximately $48,000. Jane Street Group LLC purchased a new position in shares of Werewolf Therapeutics during the 2nd quarter worth approximately $409,000. Finally, Bank of America Corp DE raised its stake in shares of Werewolf Therapeutics by 1.2% during the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after buying an additional 25,882 shares in the last quarter. 64.84% of the stock is owned by hedge funds and other institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.